<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Albireo Pharma, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Albireo Pharma, Inc.

    Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Ron Cooper
    • FOUNDED
      2003
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Reliv International, Inc.

    Reliv International, Inc.

    Reliv International, based in Chesterfield, MO, produces nutritional supplements t...

    Reliv International, based in Chesterfield, MO,...

    Filing Type:    PU
    ObsEva SA

    ObsEva SA

    Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company foc...

    Founded in November 2012, ObsEva is a clinical-...

    Filing Type:    PU
    Exact Sciences Corporation

    Exact Sciences Corporation

    Exact Sciences Corp. (NASDAQ: EXAS) is committed to playing a role in the eradicat...

    Exact Sciences Corp. (NASDAQ: EXAS) is committe...

    Filing Type:    PU
    Allena Pharmaceuticals, Inc.

    Allena Pharmaceuticals, Inc.

    Allena’s lead product candidate, reloxaliase, is a first-in-class, oral enzyme t...

    Allena’s lead product candidate, reloxaliase,...

    Filing Type:    PU
    Lifevantage Corporation

    Lifevantage Corporation

    LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in Nutrigenomics - a new scien...

    LifeVantage Corporation (Nasdaq: LFVN) is a pio...

    Filing Type:    PU
    Anchiano Therapeutics Ltd.

    Anchiano Therapeutics Ltd.

    We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on...

    We are Anchiano Therapeutics, a pivotal-stage b...

    Filing Type:    PU
    Galmed Pharmaceuticals Ltd.

    Galmed Pharmaceuticals Ltd.

    Galmed is a clinical-stage biopharmaceutical company focused on the development of...

    Galmed is a clinical-stage biopharmaceutical co...

    Filing Type:    PU
    Conatus Pharmaceuticals Inc.

    Conatus Pharmaceuticals Inc.

    Conatus Pharmaceuticals is a biotechnology company focused on the development and ...

    Conatus Pharmaceuticals is a biotechnology comp...

    Filing Type:    PU
    Intercept Pharmaceuticals, Inc.

    Intercept Pharmaceuticals, Inc.

    Intercept is a biopharmaceutical company focused on the development and commercial...

    Intercept is a biopharmaceutical company focuse...

    Filing Type:    PU
    Redhill Biopharma Ltd.

    Redhill Biopharma Ltd.

    RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a special...

    RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv...

    Filing Type:    PU
    Evoke Pharma, Inc.

    Evoke Pharma, Inc.

    Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused pr...

    Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialt...

    Filing Type:    PU
    Edesa Biotech, Inc.

    Edesa Biotech, Inc.

    Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...

    Edesa Biotech Inc. is a clinical-stage biopharm...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.